DRKS00022375招募中未知
Role of liquid biopsy, analysis of circulating tumor cells and organoids in the diagnostic and therapy of upper-GI and hepato-pancreatico-bilary cancers (GI- and HPB-CA) - LiBiCO
niversitätsklinik für innere Medizin - Gastroenterologie, Klinikum Oldenburg0 个研究点目标入组 150 人开始时间: 2022年8月30日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- 入组人数
- 150
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- N/a: Single Arm Study
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 18 Years 至 99 Years（—）
- 性别
- All
入选标准
- •Patients with GI- and HPB-CA
排除标准
- •Patients with poor condition who cannot tolerate chemotherapy and targeted therapy.
- •Patients with impaired organ functions, heart failure (New York Heart Association III-IV), coronary heart disease, myocardial infarction within 6 months, severe cardiac arrhythmia and respiratory failure.
- •Patients diagnosed with other cancer within 5 years.
- •Patients who are pregnant or breastfeeding.
- •Patients enrolled in other clinical trials or incompliant of regular follow up.
- •Patients who did not provide an informed consent.
研究者
相似试验
尚未招募
不适用
Liquid Biopsy for the Diagnosis of Intestinal-type Adenocarcinoma of the Ethmoid (BLADE)Ethmoid Sinus TumorAdenocarcinomaCirculating Tumor CellNCT06090214University Hospital, Montpellier42
已完成
不适用
Diagnostic Accuracy of Circulating Tumor Cells (CTCs) and Onco-exosome Quantification in the Diagnosis of Pancreatic Cancer - PANC-CTCPancreatic Ductal Adenocarcinoma (PDAC)NCT03032913University Hospital, Bordeaux52
Unknown
不适用
Construction and Evaluation of the Liquid Biopsy-based Early Diagnostic Model for Lung CancerHealthyPulmonary NoduleNCT04156360Shanghai Pulmonary Hospital, Shanghai, China150
进行中（未招募）
1 期
tility of analysis in blood of the evolution of the drug brigatinib for patients with lung cancer with ALK mutationsALK+ non-small cell lung cancerMedDRA version: 20.0Level: LLTClassification code: 10025055Term: Lung cancer non-small cell stage IV Class: 10029104CTIS2024-511317-38-00Fundacion GECP33
进行中（未招募）
1 期
tility of analysis in blood of the evolution of the drug brigatinib for patients with lung cancer with ALK mutationsALK+ non-small cell lung cancerMedDRA version: 20.0Level: LLTClassification code 10025055Term: Lung cancer non-small cell stage IVSystem Organ Class: 100000004864EUCTR2019-002369-36-ESFundación GECP30